BEAM - Beam Therapeutics Inc

BEAM - Beam Therapeutics Inc

https://beamtx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Why Is Allogene Therapeutics ( ALLO ) Up 9.4% Since Last Earnings Report?

Zacks Commentary • 3 days ago • score: 0.04

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

Zacks Commentary • 2 weeks, 4 days ago • score: 0.24

CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - Beam Therapeutics ( NASDAQ:BEAM )

Benzinga • 3 weeks ago • score: 0.34

CAMBRIDGE, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE )

Benzinga • 4 weeks, 2 days ago • score: 0.28

Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing. Pfizer Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$35.25

52W Low

$13.53

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.15

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.03

EV/Revenue (<3 favorable)

18.53

P/S (TTM) (<3 favorable)

35.05

P/B (<3 favorable)

2.02

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.19%

Institutions (25–75% balanced)

105.17%

Shares Outstanding

101,162,000

Float

87,015,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

60,272,000

Gross Profit (TTM)

-301,404,992

EPS (TTM)

-4.50

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-14.19%

ROE (TTM) (>15% strong)

-0.42%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.28

Momentum

Bearish momentum

Value

0.8924

Previous

0.8234

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025